脑膜炎球菌性疾病的流行及疫苗免疫策略进展

唐继海; 刘志荣

PDF(852 KB)

安徽预防医学杂志 ›› 2019, Vol. 25 ›› Issue (6) : 456-460.

综述

脑膜炎球菌性疾病的流行及疫苗免疫策略进展

唐继海, 刘志荣

作者信息 +

Meningococcal diseases: epidemic status and progress of vaccine immunization strategies

TANG Jihai, LIU Zhirong

Author information +

文章历史 +

摘要

脑膜炎奈瑟球菌(Neisseria meningitidis,Nm)有13个血清群,其中A、B、C、W、X和Y群可引起侵袭性脑膜炎球菌病(Invasive Meningococcal Disease,IMD)。Nm引起的IMD呈全球性分布,A群一直是全球流行的主要病原,B、C群主要在工业化国家流行,W群是引起非洲IMD大流行的血清群,X、Y群引起的病例相当少见。目前,含有A、B、C、W和Y群成分的单价和多价Nm疫苗在全球范围内使用。根据不同国家和地区IMD流行特点,通过采取Nm疫苗常规接种和群体性接种的免疫策略,可以明显降低IMD的流行,从而实现阻断Nm传播。

Abstract

Neisseria meningidis (Nm) has 13 serum groups, among which A, B, C, W, X and Y serogroups can cause invasive meningococcal disease (IMD). IMD caused by Nm has a global distribution. Serogroup A has been the main pathogen of global epidemic,while serogroup B and serogroup C are mainly prevalent in industrialized countries. Group W has caused IMD outbreaks in Africa, however, the cases caused by group X and group y are quite rare. At present, monovalent and multivalent meningococcal vaccines containing serogroup A, B, C, W and Y components are used worldwide. According to the epidemic characteristics of IMD in different countries, the prevalence of IMD can be significantly reduced and the transmission of Nm can be blocked by the immunization strategies of routine vaccination and mass vaccination.

导出引用

唐继海, 刘志荣. 脑膜炎球菌性疾病的流行及疫苗免疫策略进展[J]. 安徽预防医学杂志. 2019, 25(6): 456-460

TANG Jihai, LIU Zhirong. Meningococcal diseases: epidemic status and progress of vaccine immunization strategies[J]. Anhui Journal of Preventive Medicine. 2019, 25(6): 456-460

中图分类号： R186

参考文献

[1] 邓璇,姚苹苹,何寒青,等.2006-2017年浙江省流行性脑脊髓膜炎流行病学特征及菌群变迁趋势分析[J].疾病监测,2018,33(7):547-551.
[2] Stein-Zamir C,Shoob H,Sokolov I,et al.The clinical features and long-term sequelae of invasive meningococcal disease in children[J].The Pediatric infectious disease journal,2014,33(7):777-779.
[3] 戴德芳,李放军,夏昕,等.1951-2016年湖南省流行性脑脊髓膜炎流行病学特征及菌群变迁趋势分析[J].实用预防医学,2017(12):1440-1442.
[4] Lingani C,Bergeron-Caron C,Stuart JM,et al.Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004-2013[J].Clin Infect Dis,2015,61(Suppl 5):S410-415.
[5] Gana G J,Badung S,Bunza A U,et al.Outbreak of Cerebrospinal Meningitis in Kebbi State,Nigeria[J].Annals of Ibadan Postgraduate Medicine,2017,15(1):23-28.
[6] Grodet C, Dequin PF, Watt S, et al.Outbreak in France of Neisseria meningitidis B:15:P1.12 belonging to sequence type 1403[J].Clinical microbiology and infection,2004,10(9):845-848.
[7] Folaranmi T,Rubin L,Martin SW,et al.Use of Serogroup B Meningococcal Vaccines in Persons Aged >/=10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices,2015[J].MMWR,2015,64(22):608-612.
[8] Mandal S, Wu HM, MacNeil JR, et al.Prolonged university outbreak of meningococcal disease associated with a serogroup B strain rarely seen in the United States[J].Clinical infectious diseases,2013,57(3):344-348.
[9] Fisher EA, Poissant T,Luedtke P,et al.Evaluation of Mass Vaccination Clinics in Response to a Serogroup B Meningococcal Disease Outbreak at a Large, Public University-Oregon,2015[J].The Journal of adolescent health,2018,63(2):151-156.
[10] Biswas HH, Han GS, Wendorf K, et al.Notes from the Field: Outbreak of Serogroup B Meningococcal Disease at a University-California, 2016[J].MMWR, 2016,65(20):520-521.
[11] Trotter CL,Andrews NJ,Kaczmarski EB,et al.Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction[J].Lancet.24-30 2004,364(9431):365-367.
[12] Sadarangani M,Scheifele D W,Halperin S A,et al.The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012[J].Clinical Infectious Diseases, 2014,59(9):1208-1215.
[13] Zhao S, Lin Q, He D, et al.Meningitis Epidemics Shift in sub-Saharan Belt[J].International Journal of Infectious Diseases.2018,68:79-82.
[14] Hossain MJ,Roca A,Mackenzie GA,et al.Serogroup W135 meningococcal disease,The Gambia,2012[J].Emerging infectious diseases.2013,19(9):1507-1510.
[15] Carville KS,Stevens K,Sohail A,et al.Increase in Meningococcal Serogroup W Disease, Victoria, Australia, 2013-2015.Emerging infectious diseases.2016,22(10):1785-1787.
[16] Aguilera JF,Perrocheau A,Meffre C,et al.Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.Emerging infectious diseases.2002,8(8):761-767.
[17] Tsang R S, Deeks S L, Wong K, et al.Invasive serogroup W Neisseria meningitidis, (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1,2009 to June 30,2016[J].Can Commun Dis Rep, 2016,42(12):263-266.
[18] Campbell H, Parikh S R, Borrow R, et al.Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016.[J].Euro Surveill, 2016,21(12):pii=30175.
[19] Agnememel A, Hong E, Giorgini D, et al.Neisseria meningitidis Serogroup X in Sub-Saharan Africa[J].Emerging Infectious Diseases, 2016,22(4):698-702.
[20] Rosenstein NE, Perkins BA, Stephens DS, et al.The changing epidemiology of meningococcal disease in the United States, 1992-1996[J].The Journal of infectious diseases.1999,180(6):1894-1901.
[21] Ladhani SN,Lucidarme J,Newbold LS,et al.Invasive meningococcal capsular group Y disease,England and Wales,2007-2009[J].Emerging infectious diseases.2012,18(1):63-70.
[22] 李军宏,李艺星,邵祝军,等.2009年中国流行性脑脊髓膜炎监测结果分析[J].疾病监测,2010,25(10):770-773.
[23] 刘丹青,王斌冰,陈霞,等.安徽省流行性脑脊髓膜炎流行病学分析及防制对策[J].中国疫苗和免疫,2006,12(1):40-43.
[24] 李军宏,李艺星,尹遵栋,等.中国2008～2013年C群流行性脑脊髓膜炎流行病学及临床特征分析[J].中国疫苗和免疫,2015,21(2):168-172.
[25] 原灵,詹銮峰,林震宇.福建省首例W135群流行性脑脊髓膜炎病例的回顾性研究[J].疾病监测,2010,25(3):195-196.
[26] 郭立春,刘晓川,徐庆杨,等.天津市首例Y群流行性脑脊髓膜炎病例流行病学调查[J].中华预防医学杂志.2016,50(9):825-827.
[27] 张恒,潘金仁,姚苹苹,等.浙江省首例X群流行性脑脊髓膜炎病例调查分析[J].中华预防医学杂志,2015,49(6):579-580.
[28] Chen C, Zhang TG, He JG,et al.A first meningococcal meningitis case caused by serogroup X Neisseria meningitidis strains in China[J].Chinese medical journal.2008,121(7):664-666.
[29] 李军宏,李艺星,吴丹,等.中国2006～2014年流行性脑脊髓膜炎病例菌群分布特征及变迁趋势[J].中国疫苗和免疫,2015,21(5):481-485.
[30] Ismail AA,Harris SL,Granoff DM.Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic[J].The Pediatric infectious disease journal.2004,23(8):748-755.
[31] 滕冲,尹遵栋,李艺星,等.15岁及以下儿童接种国产脑膜炎球菌疫苗免疫原性的Meta分析[J].中国预防医学杂志,2017,18(7):527-533.
[32] Campbell H,Andrews N, Borrow R,et al.Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity[J].Clinical & Vaccine Immunology Cvi,2010,17(5):840-847.
[33] Mulhall RM, Bennett D, Cunney R, et al.Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B Neisseria meningitidis Isolated from 2009 to 2013 in the Republic of Ireland.mSphere.2018,3(4):e00196-18.
[34] Okwo-Bele JM, LaForce FM, Borrow R, Preziosi MP.Documenting the Results of a Successful Partnership: A New Meningococcal Vaccine for Africa.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.2015,61(Suppl 5):S389-390.
[35] Home C.Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older--United States, 2013.[J].MMWR Supplements,2013,62(1):2-8.
[36] Pollard AJ, Riordan A, Ramsay M.Group B meningococcal vaccine: recommendations for UK use[J].Lancet.2014,383(9923):1103-1104.
[37] Campbell H, Saliba V, Borrow R, et al.Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015[J].Euro Surveill,2015,20(28):pii=21188.
[38] 刁连东.关于使用脑膜炎球菌疫苗的建议[J].中国疫苗和免疫, 2009,15(2):182-183.
[39] 唐继海,罗献伟,陈霞,等.安徽省流行性脑脊髓膜炎空间自相关分析.中国疫苗和免疫[J].2015,21(4):369-372.